Press coverage about Arbutus Biopharma Corporation (NASDAQ:ABUS) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arbutus Biopharma Corporation earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.7865712840405 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Arbutus Biopharma Corporation (NASDAQ:ABUS) opened at $6.20 on Monday. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma Corporation has a twelve month low of $2.35 and a twelve month high of $8.25.

Several brokerages have weighed in on ABUS. JMP Securities reiterated an “outperform” rating and issued a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma Corporation in a research report on Wednesday, October 4th. ValuEngine upgraded Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st. Wedbush reiterated an “outperform” rating and issued a $9.00 price objective on shares of Arbutus Biopharma Corporation in a research report on Wednesday, September 20th. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma Corporation in a research report on Wednesday, September 13th. Finally, Zacks Investment Research upgraded Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $15.00.

TRADEMARK VIOLATION NOTICE: “Arbutus Biopharma Corporation (ABUS) Earning Somewhat Favorable News Coverage, Report Finds” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/arbutus-biopharma-corporation-abus-earning-somewhat-favorable-news-coverage-report-finds/1683101.html.

In other news, insider Michael J. Sofia sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total value of $80,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael J. Sofia sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $3.70, for a total transaction of $111,000.00. Following the completion of the transaction, the insider now owns 1,563,403 shares of the company’s stock, valued at $5,784,591.10. The disclosure for this sale can be found here. Company insiders own 10.00% of the company’s stock.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.